Pretargeting for imaging and therapy in oncological nuclear medicine

Pretargeting for imaging and therapy in oncological nuclear medicine

Abstract Background Oncological pretargeting has been implemented and tested in several different ways in preclinical models and clinical trials over more than 30 years. Despite highly promising results, pretargeting has not achieved market approval even though it could be considered the ultimate th...

Full description

Bibliographic Details
Main Authors: Clément Bailly, Caroline Bodet-Milin, Caroline Rousseau, Alain Faivre-Chauvet, Françoise Kraeber-Bodéré, Jacques Barbet
Format: Article
Language:English
Published: SpringerOpen 2017-06-01
Series:EJNMMI Radiopharmacy and Chemistry
Subjects:
Pretargeting
Immunoscintigraphy
ImmunoPET
Radioimmunotherapy
Bispecific antibody
Avidin-biotin
Online Access:http://link.springer.com/article/10.1186/s41181-017-0026-8

Internet

http://link.springer.com/article/10.1186/s41181-017-0026-8

Similar Items